Bacteriophages, viruses that specifically infect bacteria, emerge as precision tools to combat multidrug-resistant infections and modulate host immunity. This review explores the dynamic interactions between bacteriophages and both bacterial and eukaryotic hosts, emphasizing their therapeutic potential and biotechnological applications. We discuss mechanisms of phage entry into mammalian tissues, including traversal of the blood–brain barrier, and their roles in shaping innate and adaptive immune responses. The review also highlights advances in phage engineering, such as non-lytic phagemid systems, clustered regularly interspersed short palindromic repeats (CRISPR)-based antimicrobials, and quorum-sensing disruption strategies. These innovations position bacteriophages as versatile agents in modern microbiology, with implications for personalized medicine, immunotherapy, and synthetic biology.
StoneE, CampbellK, GrantI, et al.Understanding and exploiting phage–host interactions. Viruses, 2019; 11(6): 526–567; doi: 10.3390/v11060567
3.
KutterE, BryanD, RayG, et al.From host to phage metabolism: Hot tales of phage T4’s takeover of E. Coli. Viruses, 2018; 10(7):387; doi: 10.3390/v10070387
4.
MillerES, KutterE, MosigG, et al.Bacteriophage T4 genome. Microbiol Mol Biol Rev, 2003; 67(1):86–156, table of contents; doi: 10.1128/mmbr.67.1.86-156.2003
5.
WarnerHR, SnustadDP, JorgensenSE, et al.Isolation of bacteriophage T4 mutants defective in the ability to degrade host deoxyribonucleic acid 1. J Virol, 1970; 5(6):700–708; doi: 10.1128/jvi.5.6.700-708.1970
6.
Drulis-KawaZ. Special Issue: Phage–Bacteria Interplay in Health and Disease. 2022.
7.
YazdiM, BouzariM, Ghaemi EzzatA, et al.Isolation, characterization and genomic analysis of a novel bacteriophage VB_ecoS-Golestan infecting multidrug-resistant Escherichia coli isolated from urinary tract infection. Sci Rep, 2020; 10(1):7690; doi: 10.1038/s41598-020-63048-x
8.
MihindukulasuriyaKA, MarsRAT, JohnsonAJ, et al.Multi-omics analyses show disease, diet, and transcriptome interactions with the virome. Gastroenterology, 2021; 161(4):1194–1207.e8; doi: 10.1053/j.gastro.2021.06.077
9.
HuhH, WongS, St. JeanJ, et al.Bacteriophage interactions with mammalian tissue: Therapeutic applications. Adv Drug Deliv Rev, 2019; 145:4–17; doi: 10.1016/j.addr.2019.01.003
10.
EgawaG, NakamizoS, NatsuakiY, et al.Intravital analysis of vascular permeability in mice using two-photon microscopy. Sci Rep, 2013; 3:1932–1936; doi: 10.1038/srep01932
11.
GórskiA, WaznaE, DabrowskaB-W, et al.Bacteriophage translocation. FEMS Immunol Med Microbiol, 2006; 46(3):313–319; doi: 10.1111/j.1574-695X.2006.00044.x
DabrowskaK, Switała-JelenK, OpolskiA, et al.A review: Bacteriophage penetration in vertebrates. J Appl Microbiol, 2005; 98(1):7–13; doi: 10.1111/j.1365-2672.2004.02422.x
14.
PorayathC, SalimA, Palillam VeeduA, et al.Characterization of the bacteriophages binding to human matrix molecules. Int J Biol Macromol, 2018; 110:608–615; doi: 10.1016/j.ijbiomac.2017.12.052
15.
NguyenS, BakerK, PadmanBS, et al.Bacteriophage transcytosis provides a mechanism to cross epithelial cell layers. mBio, 2017; 8(6):e01874–e01817; doi: 10.1128/mBio.01874-17
16.
DohertyGJ, McMahonHT. Mechanisms of endocytosis. Annu Rev Biochem, 2009; 78(1):857–902; doi: 10.1146/annurev.biochem.78.081307.110540
17.
RehmanS, AliZ, KhanM, et al.The dawn of phage therapy. Rev Med Virol, 2019; 29(4):e2041; doi: 10.1002/rmv.2041
18.
KimA, ShinTH, ShinSM, et al.Cellular internalization mechanism and intracellular trafficking of filamentous M13 phages displaying a cell-penetrating transbody and TAT peptide. PLoS One, 2012; 7(12):e51813; doi: 10.1371/journal.pone.0051813
19.
DuerrDM, WhiteSJ, SchluesenerHJ. Identification of peptide sequences that induce the transport of phage across the gastrointestinal mucosal barrier. J Virol Methods, 2004; 116(2):177–180; doi: 10.1016/j.jviromet.2003.11.012
20.
LehtiTA, PajunenMI, SkogMS, et al.Internalization of a polysialic acid-binding Escherichia coli bacteriophage into eukaryotic neuroblastoma cells. Nat Commun, 2017; 8(1):1915; doi: 10.1038/s41467-017-02057-3
21.
DubosRJ, StrausJH, PierceC. The multiplication of bacteriophage in vivo and its protective effect against an experimental infection with Shigella dysenteriae. J Exp Med, 1943; 78(3):161–168; doi: 10.1084/jem.78.3.161
22.
FrenkelD, SolomonB. Filamentous phage as vector-mediated antibody delivery to the brain. Proc Natl Acad Sci U S A, 2002; 99(8):5675–5679; doi: 10.1073/pnas.072027199
23.
WuLP, AhmadvandD, SuJ, et al.Crossing the blood-brain-barrier with nanoligand drug carriers self-assembled from a phage display peptide. Nat Commun, 2019; 10(1):4635; doi: 10.1038/s41467-019-12554-2
24.
HaqqaniAS, BélangerK, StanimirovicDB. Receptor-mediated transcytosis for brain delivery of therapeutics: Receptor classes and criteria. Front Drug Deliv, 2024; 4:1360302; doi: 10.3389/fddev.2024.1360302
25.
AshworthEA, WrightRCT, ShearsRK, et al.Exploiting lung adaptation and phage steering to clear pan-resistant Pseudomonas aeruginosa infections in vivo. Nat Commun, 2024; 15(1):1547; doi: 10.1038/s41467-024-45785-z
26.
KammeC. Antibodies against staphylococcal bacteriophages in human sera: I. Assay of antibodies in healthy individuals and in patients with staphylococcal infections. Acta Pathol Microbiol Scand B Microbiol Immunol, 1973; 81B(6):741–748; doi: 10.1111/j.1699-0463.1973.tb02269.x
27.
Van BelleghemJD, DąbrowskaK, VaneechoutteM, et al.Interactions between bacteriophage, bacteria, and the mammalian immune system. Viruses, 2018; 11(1):10; doi: 10.3390/v11010010
28.
DuerkopBA, HooperLV. Resident viruses and their interactions with the immune system. Nat Immunol, 2013; 14(7):654–659; doi: 10.1038/ni.2614
29.
KrutO, Bekeredjian-DingI. Contribution of the immune response to phage therapy. J Immunol, 2018; 200(9):3037–3044; doi: 10.4049/jimmunol.1701745
30.
DufourN, DelattreR, RicardJD, et al.The lysis of pathogenic Escherichia coli by bacteriophages releases less endotoxin than by β-lactams. Clin Infect Dis, 2017; 64(11):1582–1588; doi: 10.1093/cid/cix184
31.
DąbrowskaK, MiernikiewiczP, PiotrowiczA, et al.Immunogenicity studies of proteins forming the T4 phage head surface. J Virol, 2014; 88(21):12551–12557; doi: 10.1128/jvi.02043-14
32.
MajewskaJ, BetaW, LecionD, et al.Oral application of T4 phage induces weak antibody production in the gut and in the blood. Viruses, 2015; 7(8):4783–4799; doi: 10.3390/v7082845
33.
PincusNB, ReckhowJD, SaleemD, et al.Strain specific phage treatment for Staphylococcus aureus infection is influenced by host immunity and site of infection. PLoS One, 2015; 10(4):e0124280; doi: 10.1371/journal.pone.0124280
34.
Łusiak-SzelachowskaM, ZaczekM, Weber-DabrowskaB, et al.Phage neutralization by sera of patients receiving phage therapy. Viral Immunol, 2014; 27(6):295–304; doi: 10.1089/vim.2013.0128
Hodyra-StefaniakK, MiernikiewiczP, DrapałaJ, et al.Mammalian host-versus-phage immune response determines phage fate in vivo. Sci Rep, 2015; 5:14802; doi: 10.1038/srep14802
37.
Jończyk-MatysiakE, Łusiak-SzelachowskaM, KłakM, et al.The effect of bacteriophage preparations on intracellular killing of bacteria by phagocytes. J Immunol Res, 2015; 2015:482863; doi: 10.1155/2015/482863
38.
DufourN, HenryM, RicardJD, et al.Commentary: Morphologically distinct Escherichia coli bacteriophages differ in their efficacy and ability to stimulate cytokine release in vitro. Front Microbiol, 2016; 7(JUN):1029; doi: 10.3389/fmicb.2016.01029
BarfootR, DenhamS, GyureLA, et al.Some properties of dendritic macrophages from peripheral lymph. Immunology, 1989; 68(2):233–239.
41.
PrzerwaA, ZimeckiM, Switała-JeleńK, et al.Effects of bacteriophages on free radical production and phagocytic functions. Med Microbiol Immunol, 2006; 195(3):143–150; doi: 10.1007/s00430-006-0011-4
42.
AnTW, KimSJ, LeeYD, et al.The immune-enhancing effect of the Cronobacter sakazakii ES2 phage results in the activation of nuclear factor-κB and dendritic cell maturation via the activation of IL-12p40 in the mouse bone marrow. Immunol Lett, 2014; 157(1–2):1–8; doi: 10.1016/j.imlet.2013.10.007
43.
TandleA, HannaE, LorangD, et al.Tumor vasculature-targeted delivery of tumor necrosis factor-α. Cancer, 2009; 115(1):128–139; doi: 10.1002/cncr.24001
44.
WeissfussC, WienholdS-M, BürkleM, et al.Repetitive exposure to bacteriophage cocktails against Pseudomonas aeruginosa or Escherichia coli provokes marginal humoral immunity in naïve mice. Viruses, 2023; 15(2):387; doi: 10.3390/v15020387
45.
RhoadsDD, WolcottRD, KuskowskiMA, et al.Bacteriophage therapy of venous leg ulcers in humans: Results of a phase I safety trial. J Wound Care, 2009; 18(6):237–243; doi: 10.12968/jowc.2009.18.6.42801
46.
WrightA, HawkinsCH, ÄnggårdEE, et al.A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; A preliminary report of efficacy. Clin Otolaryngol, 2009; 34(4):349–357; doi: 10.1111/j.1749-4486.2009.01973.x
47.
BruttinA, BrüssowH. Human volunteers receiving Escherichia coli phage T4 orally: A safety test of phage therapy. Antimicrob Agents Chemother, 2005; 49(7):2874–2878; doi: 10.1128/AAC.49.7.2874-2878.2005
48.
SarkerSA, BrüssowH. From bench to bed and back again: Phage therapy of childhood Escherichia coli diarrhea. Ann N Y Acad Sci, 2016; 1372(1):42–52; doi: 10.1111/nyas.13087
49.
BorysowskiJ, GórskiA. Is phage therapy acceptable in the immunocompromised host? Int J Infect Dis, 2008; 12(5):466–471; doi: 10.1016/j.ijid.2008.01.006
50.
LiuD, Van BelleghemJD, de VriesCR, et al.The safety and toxicity of phage therapy: A review of animal and clinical studies. Viruses, 2021; 13(7):1268; doi: 10.3390/v13071268
51.
HattoriY, HattoriK, SuzukiT, et al.Recent advances in the pathophysiology and molecular basis of sepsis-associated organ dysfunction: Novel therapeutic implications and challenges. Pharmacol Ther, 2017; 177:56–66; doi: 10.1016/j.pharmthera.2017.02.040
52.
NemethJ, OeschG, KusterSP. Bacteriostatic versus bactericidal antibiotics for patients with serious bacterial infections: Systematic review and meta-analysis. J Antimicrob Chemother, 2015; 70(2):382–395; doi: 10.1093/jac/dku379
53.
KromRJ, BhargavaP, LobritzMA, et al.Engineered phagemids for nonlytic, targeted antibacterial therapies. Nano Lett, 2015; 15(7):4808–4813; doi: 10.1021/acs.nanolett.5b01943
54.
GerovacM, ChiharaK, WickeL, et al.Phage proteins target and co-opt host ribosomes immediately upon infection. Nat Microbiol, 2024; 9(3):787–800; doi: 10.1038/s41564-024-01616-x
55.
PeiR, Lamas-SamanamudGR. Inhibition of biofilm formation by T7 bacteriophages producing quorum-quenching enzymes. Appl Environ Microbiol, 2014; 80(17):5340–5348; doi: 10.1128/AEM.01434-14
56.
LuTK, CollinsJJ. Engineered bacteriophage targeting gene networks as adjuvants for antibiotic therapy. Proc Natl Acad Sci U S A, 2009; 106(12):4629–4634; doi: 10.1073/pnas.0800442106
57.
CumbyN, DavidsonAR, MaxwellKL. The moron comes of age. Bacteriophage, 2012; 2(4):225–228; doi: 10.4161/bact.23146
58.
FarooqU, YangQ, UllahMW, et al.Bacterial biosensing: Recent advances in phage-based bioassays and biosensors. Biosens Bioelectron, 2018; 118(July):204–216; doi: 10.1016/j.bios.2018.07.058
59.
BurnhamS, HuJ, AnanyH, et al.Towards rapid on-site phage-mediated detection of generic Escherichia coli in water using luminescent and visual readout. Anal Bioanal Chem, 2014; 406(23):5685–5693; doi: 10.1007/s00216-014-7985-3
60.
GórskiA, MiędzybrodzkiR, BorysowskiJ, et al.Phage as a modulator of immune responses. Practical implications for phage therapy. Adv Virus Res, 2012; 83:41–71; doi: 10.1016/B978-0-12-394438-2.00002-5
61.
MerrilCR, BiswasB, CarltonR, et al.Long-circulating bacteriophage as antibacterial agents. Proc Natl Acad Sci U S A, 1996; 93(8):3188–3192; doi: 10.1073/pnas.93.8.3188
62.
SinglaS, HarjaiK, KatareOP, et al.Encapsulation of bacteriophage in liposome accentuates its entry in to macrophage and shields it from neutralizing antibodies. PLoS One, 2016; 11(4):e0153777; doi: 10.1371/journal.pone.0153777
63.
KimKP, ChaJD, JangEH, et al.PEGylation of bacteriophages increases blood circulation time and reduces T-helper type 1 immune response. Microb Biotechnol, 2008; 1(3):247–257; doi: 10.1111/j.1751-7915.2008.00028.x
64.
PapudeshiB, RoachMJ, MallawaarachchiV, et al.Sphae: An automated toolkit for predicting phage therapy candidates from sequencing data. Bioinform Adv, 2025; 5(1):vbaf004; doi: 10.1093/bioadv/vbaf004
65.
AntonovicsJ, BootsM, EbertD, et al.The origin of specificity by means of natural selection: Evolved and nonhost resistance in host-pathogen interactions. Evolution, 2013; 67(1):1–9; doi: 10.1111/j.1558-5646.2012.01793.x
66.
LindowSE, BrandlMT. Microbiology of the phyllosphere MINIREVIEW microbiology of the phyllosphere. Appl Environ Microbiol, 2003; 69(4):1875–1883; doi: 10.1128/AEM.69.4.1875-1883.2003
67.
KoskellaB, TaylorTB. Multifaceted impacts of bacteriophages in the plant microbiome. Annu Rev Phytopathol, 2018; 56(1):361–380; doi: 10.1146/annurev-phyto-080417-045858
68.
WalshCM, Becker-UncapherI, CarlsonM, et al.Variable influences of soil and seed-associated bacterial communities on the assembly of seedling microbiomes. ISME J, 2021; 15(9):2748–2762; doi: 10.1038/s41396-021-00967-1
69.
MeyerKM, PorchR, MuscettolaIE, et al.Plant neighborhood shapes diversity and reduces interspecific variation of the phyllosphere microbiome. ISME J, 2022; 16(5):1376–1387; doi: 10.1038/s41396-021-01184-6
70.
LeonardS, HommaisF, NasserW, et al.Plant–phytopathogen interactions: Bacterial responses to environmental and plant stimuli. Environ Microbiol, 2017; 19(5):1689–1716; doi: 10.1111/1462-2920.13611
PoisotT, BellT, MartinezE, et al.Terminal investment induced by a bacteriophage in a rhizosphere bacterium. F1000Res, 2012; 1(May):21–14; doi: 10.12688/f1000research.1-21.v2
73.
ScanlanPD, BucklingA. Co-evolution with lytic phage selects for the mucoid phenotype of Pseudomonas fluorescens SBW25. ISME J, 2012; 6(6):1148–1158; doi: 10.1038/ismej.2011.174
74.
HernandezCA, KoskellaB. Phage resistance evolution in vitro is not reflective of in vivo outcome in a plant-bacteria-phage system*. Evolution, 2019; 73(12):2461–2475; doi: 10.1111/evo.13833
75.
SmitE, WoltersAC, LeeH, et al.Interactions between a genetically marked Pseudomonas fluorescens strain and bacteriophage ΦR2f in soil: Effects of nutrients, alginate encapsulation, and the wheat rhizosphere. Microb Ecol, 1996; 31(2):125–140; doi: 10.1007/BF00167859
76.
AshelfordKE, DayMJ, BaileyMJ, et al.In situ population dynamics of bacterial viruses in a terrestrial environment. Appl Environ Microbiol, 1999; 65(1):169–174; doi: 10.1128/aem.65.1.169-174.1999
77.
BohannanBJM, LenskiRE. Linking genetic change to community evolution: Insights from studies of bacteria and bacteriophage. Ecol Lett, 2000; 3(4):362–377; doi: 10.1046/j.1461-0248.2000.00161.x
78.
JaiswalAK, EladY, PaudelI, et al.Linking the belowground microbial composition, diversity and activity to soilborne disease suppression and growth promotion of tomato amended with biochar. Sci Rep, 2017; 7(March):44382–44317; doi: 10.1038/srep44382
79.
PirhonenM, HeinoP, HelanderI, et al.Bacteriophage T4 resistant mutants of the plant pathogen Erwinia carotovora. Microb Pathog, 1988; 4(5):359–367; doi: 10.1016/0882-4010(88)90063-0
80.
KleczkowskaJ. A study of phage-resistant mutants of Rhizobium trifolii. J Gen Microbiol, 1950; 4(3):298–310; doi: 10.1099/00221287-4-3-298
81.
MałekW. Mutants of Rhizobium meliloti defective in nodulation. J Basic Microbiol, 1988; 28(9–10):645–650; doi: 10.1002/jobm.3620280924
